Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience
نویسندگان
چکیده
منابع مشابه
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.
BACKGROUND Although recent experimental data strongly suggest that platinum-based chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC), clinical data are lacking. Here, the authors reviewed clinical outcome in patients with metastatic TNBC treated with PBCT. PATIENTS AND METHODS We conducted a retrospective analysis of all patients (N=143) treated for metastat...
متن کاملChemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy.
The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients with PBCT than those with non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but ...
متن کاملPlatinum-based chemotherapy in triple-negative breast cancer
Background: Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer. Patients and methods: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuva...
متن کاملERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxic chemotherapy that causes interstrand breaks (platinum-based drugs). The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway, removing platinum-induced DNA adducts and contributing to cisplatin resistance. Detecting ERC...
متن کاملBenefi t of Platinum-based Chemotherapy in Metastatic Triple Negative Breast Cancer
Background: Management of triple-negative breast cancer (TNBC) is challenging because of a lack of targeted therapy, its aggressive behavior and its relatively poor prognosis. Various studies showed that these tumors are highly chemosensitive and in some cases are represented by complete pathological response (pCR), but the results remains unsatisfactory.1 Recent experimental data strongly sugg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2011
ISSN: 0923-7534
DOI: 10.1093/annonc/mdq461